Explore the vast range of titles available.

We identified 4 cases of presumptive autochthonous melioidosis during 1983-2024 in Georgia, USA. Epidemiologic investigation identified no recent international travel before illness; all cases were geographically linked, and 3 patients became ill after a severe weather event. Bioinformatic analyses revealed Burkholderia pseudomallei genome sequences were highly related, suggesting a shared exposure.

Monkeypox (mpox) is a disease caused by infection with Monkeypox virus (MPXV), an Orthopoxvirus (OPXV) in the same genus as Variola virus, which causes smallpox. During 2022, a global outbreak involving mpox clade IIb was recognized, primarily among gay, bisexual, and other men who have sex with men.* Most affected patients have been immunocompetent and experienced ≤10 rash lesions (1). CDC has recommended supportive care including pain control. However, some patients have experienced severe mpox manifestations, including ocular lesions, neurologic complications, myopericarditis, complications associated with mucosal (oral, rectal, genital, and urethral) lesions, and uncontrolled viral spread due to moderate or severe immunocompromise, particularly advanced HIV infection (2). Therapeutic medical countermeasures (MCMs) are Food and Drug Administration (FDA)-regulated drugs and biologics that are predominantly stockpiled by the U.S. government; MCMs developed for smallpox preparedness or shown to be effective against other OPXVs (i.e., tecovirimat, brincidofovir, cidofovir, trifluridine ophthalmic solution, and vaccinia immune globulin intravenous [VIGIV]) have been used to treat severe mpox. During May 2022-January 2023, CDC provided more than 250 U.S. mpox consultations. This report synthesizes data from animal models, MCM use for human cases of related OPXV, unpublished data, input from clinician experts, and experience during consultations (including follow-up) to provide interim clinical treatment considerations. Randomized controlled trials and other carefully controlled research studies are needed to evaluate the effectiveness of MCMs for treating human mpox. Until data gaps are filled, the information presented in this report represents the best available information concerning the effective use of MCMs and should be used to guide decisions about MCM use for mpox patients.

In 2022, Burkholderia pseudomallei was first identified in continental United States (U.S.) environmental samples from the Mississippi Gulf Coast following two autochthonous infections. To better understand the extent of exposure to this emerging bacterium, we tested a convenience sample of 825 residual sera samples (550 from the Mississippi Gulf Coast, 275 from the northern U.S.) from a commercial diagnostic laboratory for the presence of antibodies to B. pseudomallei, using an indirect hemagglutination assay. We estimated seroprevalence of antibodies to B. pseudomallei in Mississippi Gulf Coast residents and in controls from northern regions of the U.S. where B. pseudomallei is less likely to persist in the environment. At a titer cut-off of ≥1:40, we observed a similar seropositivity between Mississippi Gulf Coast residents (14%, 95% CI: 11%, 17%) and controls (17%, 95% CI: 13%, 18%). Similarities in seropositivity suggest environmental exposure to B. pseudomallei in the Mississippi Gulf Coast may be limited; however, a lack of accompanying illness and exposure information limits our ability to conclusively interpret these findings. These estimates can serve as a baseline of seropositivity in the U.S. for future studies and to track the spread of B. pseudomallei in the U.S. over time.

Background: Throughout the COVID-19 pandemic, CDC Division of Healthcare Quality Promotion (DHQP) has provided technical assistance in support of state, tribal, local, and territorial health departments for COVID-19 healthcare outbreak management and infection prevention and control (IPC). We characterized the volume and trends of technical assistance provided during the pandemic to inform the future needs of health departments for COVID-19 healthcare IPC and DHQP resources required to meet these needs. Methods: In January 2020, DHQP began receiving COVID-19 IPC TA requests directly from health departments for remote assistance or from CDC staff on field deployments providing onsite support. DHQP subject-matter experts provided responses via e-mail or, for more complex inquiries, outbreaks, or field deployments, via phone consultations. Records of e-mail communications and phone consultations were entered into an inquiry database for tracking. We calculated the number, mean, and range of technical-assistance responses by jurisdiction and by month from January 2020 through December 2021. We designated months as high-volume periods for technical assistance if inquiries surpassed the 75th percentile. Results: In total, 1,869 IPC technical-assistance responses were provided. Of all technical-assistance responses, 1,725 (92%) were to state or local health departments, 115 (6%) were tribal nations, and 28 (2%) were US territories. IPC technical assistance was provided to all 50 states and the District of Columbia, 16 tribal nations, and 5 US territories. The average total number of technical assistance responses per site during the 24-month period was 34 to state and local HDs (range, 2–111), 6 to tribal nations (when tribal nation was specified; range, 1–17), and 6 to US territories (range, 1–15). E-mail communications comprised 1,164 responses (62%); phone consultations made up the remaining 705 responses (38%). Of phone consultations, 350 (50%) were with CDC field deployers providing onsite support to health departments. The average number of technical-assistance responses provided each month across all jurisdictions was 78 (range, 0–334); months with high volumes included April–August 2020 and January 2021. Conclusions: These findings highlight the high-level collaboration between federal and state, tribal, local, and territorial health department partners in remote and onsite support of COVID-19 prevention and response efforts in healthcare settings. Variations in monthly volumes of health-department COVID-19 healthcare IPC technical assistance requests may reflect factors such as fluctuations in community infection rates and changes in CDC IPC guidance. The ability to provide effective technical assistance during pandemic response depends on the CDC maintaining sufficient healthcare IPC staffing and expertise. Funding: None Disclosures: None

Infection with Burkholderia pseudomallei, the causative agent of melioidosis, is uncommon in the United States (U.S.), leading to delays in pathogen identification and clinical diagnosis which can often lead to laboratory exposures. The indirect hemagglutination assay (IHA) is the primary serological test for confirming exposure to B. pseudomallei. In the U.S., a titer of ≥1:40 suggests exposure to B. pseudomallei or a closely related species, and a 4-fold rise in IHA titer ≥1:40 with clinically compatible illness is considered diagnostically probable. A retrospective analysis of 160 voluntarily reported laboratory exposure events to B. pseudomallei across 29 U.S. jurisdictions and 5 countries between 2008–2024 was conducted. This analysis included post-exposure management data and IHA results for 855 exposed laboratory personnel who had serological monitoring performed at the U.S. Centers for Disease Control and Prevention (CDC). Among exposed laboratory personnel, 105 (12%) had a seropositive titer. Of these, ninety-one (87%) laboratory personnel remained seropositive (≥1:40) at their last IHA test. Five (1%) people had a 4-fold rise in titers, though none developed melioidosis. This report underscores the need for prospective studies to evaluate seropositive laboratory personnel and to update risk guidance for laboratory exposures in non-endemic areas.

Since 1997, nine cases of severe pneumonia, caused by species within the B. cereus group and with a presentation similar to that of inhalation anthrax, were reported in seemingly immunocompetent metalworkers, with most being welders. In seven of the cases, isolates were found to harbor a plasmid similar to the B. anthracis pXO1 that encodes anthrax toxins. In this paper, we review the literature on the B. cereus group spp. pneumonia among welders and other metalworkers, which we term welder’s anthrax. We describe the epidemiology, including more information on two cases of welder’s anthrax in 2020. We also describe the health risks associated with welding, potential mechanisms of infection and pathological damage, prevention measures according to the hierarchy of controls, and clinical and public health considerations. Considering occupational risk factors and controlling exposure to welding fumes and gases among workers, according to the hierarchy of controls, should help prevent disease transmission in the workplace.

Collecting additional data that are related to HAI outbreaks can help identify patient-level characteristics: race, ethnicity, sex, and sexual orientation, as well as facility-level characteristics, such as ZIP code, patient pay information, status of healthcare facility (eg, for profit or nonprofit, federally qualified health center) and facility designations (eg, health professional shortage or medically underserved area). Analysis of patient and facility-level characteristics will provide insight into both markers (eg, race, ethnicity, sex, and sexual orientation) of inequities related to outbreaks and drivers (eg, structural racism, inequity in income, inequity in healthcare access, and health insurance coverage) that perpetuate health inequities.9,10 Collection and analysis of these data are critical to inform the appropriate and equitable allocation of resources toward preventive strategies that could decrease risk of HAI outbreaks across facilities and mitigate related patient harms. To assist healthcare facilities and public health entities in collecting this information, the Centers for Disease Control and Prevention (CDC) Division of Healthcare Quality Promotion in collaboration with the Council for Outbreak Response: Healthcare-Associated Infections and Antimicrobial-Resistant Pathogens (CORHA) created a comprehensive list of patient and facility-level variables that can be collected during or following an HAI outbreak investigation (https://www.corha.org/resources-and-products/?filter_cat=data-management).

The first reported U.S. case of coronavirus disease 2019 (COVID-19) was detected in January 2020 (1). As of June 15, 2020, approximately 2 million cases and 115,000 COVID-19-associated deaths have been reported in the United States.* Reports of U.S. patients hospitalized with SARS-CoV-2 infection (the virus that causes COVID-19) describe high proportions of older, male, and black persons (2-4). Similarly, when comparing hospitalized patients with catchment area populations or nonhospitalized COVID-19 patients, high proportions have underlying conditions, including diabetes mellitus, hypertension, obesity, cardiovascular disease, chronic kidney disease, or chronic respiratory disease (3,4). For this report, data were abstracted from the medical records of 220 hospitalized and 311 nonhospitalized patients aged ≥18 years with laboratory-confirmed COVID-19 from six acute care hospitals and associated outpatient clinics in metropolitan Atlanta, Georgia. Multivariable analyses were performed to identify patient characteristics associated with hospitalization. The following characteristics were independently associated with hospitalization: age ≥65 years (adjusted odds ratio [aOR] = 3.4), black race (aOR = 3.2), having diabetes mellitus (aOR = 3.1), lack of insurance (aOR = 2.8), male sex (aOR = 2.4), smoking (aOR = 2.3), and obesity (aOR = 1.9). Infection with SARS-CoV-2 can lead to severe outcomes, including death, and measures to protect persons from infection, such as staying at home, social distancing (5), and awareness and management of underlying conditions should be emphasized for those at highest risk for hospitalization with COVID-19. Measures that prevent the spread of infection to others, such as wearing cloth face coverings (6), should be used whenever possible to protect groups at high risk. Potential barriers to the ability to adhere to these measures need to be addressed.

Bacillus cereus group bacteria containing the anthrax toxin genes can cause fatal anthrax pneumonia in welders. Two welder’s anthrax cases identified in 2020 were investigated to determine the source of each patient’s exposure. Environmental sampling was performed at locations where each patient had recent exposure to soil and dust. Samples were tested for the anthrax toxin genes by real-time PCR, and culture was performed on positive samples to identify whether any environmental isolates matched the patient’s clinical isolate. A total of 185 environmental samples were collected in investigation A for patient A and 108 samples in investigation B for patient B. All samples from investigation B were real-time PCR-negative, but 14 (8%) samples from investigation A were positive, including 10 from patient A’s worksite and 4 from his work-related clothing and gear. An isolate genetically matching the one recovered from patient A was successfully cultured from a worksite soil sample. All welder’s anthrax cases should be investigated to determine the source of exposure, which may be linked to their worksite. Welding and metalworking employers should consider conducting a workplace hazard assessment and implementing controls to reduce the risk of occupationally associated illnesses including welder’s anthrax.

Long-term exposure to welding and metalworking fumes is associated with various forms of lung injury that can cause changes in lung function and increase susceptibility to pulmonary infections, including fatal pneumonia.§ An investigation by CDC at one patient’s worksite in Louisiana (patient F) identified a bacterial isolate in a soil sample that genetically matched a clinical isolate from the patient. Several actions can decrease risk for lung injury or infection, including anthrax pneumonia caused by B. cereus group bacteria, among welders and other metalworkers. Because of the association between welding or metalworking and pulmonary infections or injury, it is important that employers educate workers regarding hazards associated with welding and measures they can take to minimize potential exposures. [...]employers should conduct a hazard assessment at worksites and consider the use of National Institute for Occupational Safety and Health–approved respirators as part of a written respiratory protection program.¶,** Clinicians should consider B. cereus group bacteria in the differential diagnosis when treating welders and other metalworkers with severe, rapidly progressive pneumonia or other anthrax-like disease.†† B. cereus group bacteria identified on culture are not always contaminants; when B. cereus with anthrax toxin is suspected, laboratorians and clinicians should pursue additional testing through their state Laboratory Response Network laboratory.§§ Regional health departments and the Laboratory Response Network serve pivotal roles in pathogen detection and procuring anthrax antitoxin for confirmed cases.